Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy A Novel Form of Tumor Progression

Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase... ORIGINAL ARTICLE Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy A Novel Form of Tumor Progression Bernadette Liegl, MD,*w Jason L. Hornick, MD, PhD,* Cristina R. Antonescu, MD,z Christopher L. Corless, MD,y and Christopher D. M. Fletcher, MD, FRCPath* mutations were detected in both the conventional GIST and Abstract: Approximately 80% of advanced metastatic gastro- rhabdomyoblastic components from all patients: KIT exon intestinal stromal tumors (GISTs) respond to treatment with the 11 mutations in 4 cases and a platelet-derived growth factor tyrosine kinase inhibitor (TKI) imatinib mesylate. However, the receptor a gene exon 18 deletion in 1 case. No secondary majority of patients suffer disease progression at a median of 2 mutations of the type associated with TKI resistance were years due to drug resistance. In general, progressing GISTs identified in the rhabdomyoblastic areas. This is the first report retain their typical morphology. Herein, we report 5 cases of of rhabdomyoblastic differentiation occurring in GISTs that progressing metastatic GIST with heterologous rhabdomyo- progressed on TKI therapy. It is associated with loss of KIT blastic differentiation after TKI treatment. Histologic, immu- expression, but retention of the receptor tyrosine kinase nohistochemical, and mutational analyses were performed on mutation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Surgical Pathology Wolters Kluwer Health

Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy A Novel Form of Tumor Progression

Loading next page...
 
/lp/wolters-kluwer-health/rhabdomyosarcomatous-differentiation-in-gastrointestinal-stromal-rCBsGtdycN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0147-5185
eISSN
1532-0979
DOI
10.1097/PAS.0b013e31817ec2e6
pmid
18830121
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy A Novel Form of Tumor Progression Bernadette Liegl, MD,*w Jason L. Hornick, MD, PhD,* Cristina R. Antonescu, MD,z Christopher L. Corless, MD,y and Christopher D. M. Fletcher, MD, FRCPath* mutations were detected in both the conventional GIST and Abstract: Approximately 80% of advanced metastatic gastro- rhabdomyoblastic components from all patients: KIT exon intestinal stromal tumors (GISTs) respond to treatment with the 11 mutations in 4 cases and a platelet-derived growth factor tyrosine kinase inhibitor (TKI) imatinib mesylate. However, the receptor a gene exon 18 deletion in 1 case. No secondary majority of patients suffer disease progression at a median of 2 mutations of the type associated with TKI resistance were years due to drug resistance. In general, progressing GISTs identified in the rhabdomyoblastic areas. This is the first report retain their typical morphology. Herein, we report 5 cases of of rhabdomyoblastic differentiation occurring in GISTs that progressing metastatic GIST with heterologous rhabdomyo- progressed on TKI therapy. It is associated with loss of KIT blastic differentiation after TKI treatment. Histologic, immu- expression, but retention of the receptor tyrosine kinase nohistochemical, and mutational analyses were performed on mutation

Journal

American Journal of Surgical PathologyWolters Kluwer Health

Published: Feb 1, 2009

There are no references for this article.